Denosumab, a monoclonal antibody targeting the receptor activator of nuclear factor kappa-b ligand, has potent antiresorptive actions in bone by blocking osteoclast formation, function, and survival [31] and has been used to treat refractory hypercalcemia associated with PC [32]. Here, TNFSF11 is linked to pachyonychia congenita.